“It is known that during aging, the function of the nervous system deteriorates over time (senescence), which may result in age-related disorders, such as a higher susceptibility to infectious diseases, autoimmune and degenerative processes, or cancer.
Photobiomodulation (PBM) is a non-pharmacological therapy that has a promising application to treat diverse neurological illnesses linked to age, such as AD and PD.
It has been observed that PBM increases cerebral blood flow and energy metabolism in the brain, and it also has antioxidant effects. Also, one of the most accepted theories about the effects of PBM postulates that it causes activation of the mitochondrial enzyme cytochrome c oxidase (CCO), leading to an increase in the production of mitochondrial adenosine triphosphate (ATP), which, in turn, may improve the cell’s metabolic activity.”
Recently, photobiomodulation, the application of red to infrared light (λ=600-1000nm) on body tissues has been reported to alter the course of aged decline. These wavelengths are absorbed by cytochrome c oxidase, the rate limiting enzyme in mitochondrial respiration, increasing its activity along with mitochondrial membrane potential and ATP production
In conclusion, photobiomodulation has been shown to alter the course of ageing in the central nervous system, by improving the survival and function of neurons and reducing gliosis and inflammation
PBM relies on the presence of chromophores, several of which exist in the mitochondrial membrane. By absorbing photons, these chromophores can induce different signaling pathways, and thus allow light to influence overall mitochondria and cell behavior.”
“By applying three consecutive treatments at 24-h intervals, we were able to obtain a lasting rejuvenating effect on aged MSCs. Our findings are of particular significance for improving autologous stem cell transplantation in older individuals who need such therapies most”